LISI S.A.

M&A Activity • Jul 9, 2025

Paris (France), July 9, 2025.

LISI GROUP has entered into exclusive negotiations with SK CAPITAL to acquire its LISI MEDICAL division

SK CAPITAL, a US transformational private investment firm, submitted a firm offer to LISI GROUP today in order to acquire all subsidiaries forming together the LISI MEDICAL division (meaning LISI MEDICAL - Head office in Neyron, LISI MEDICAL ORTHOPAEDICS - Caen, LISI MEDICAL FASTENERS - Neyron and LISI MEDICAL REMMELE - Minneapolis US).

Additionally, LISI Group is considering becoming a partner in SK CAPITAL's development strategy by taking an approximately 10% stake in the holding company that will hold these activities acquired by SK CAPITAL, thus joining the proposed transformation project.

LISI MEDICAL is specializing in medical device subcontracting, particularly orthopedic implants and minimally invasive surgery instruments. The division produces and packages machined products in titanium, chrome-cobalt and high-technology stainless steel for joint reconstruction (hip, knee, shoulder), traumatology, spine and minimally invasive surgery.

With €185.3M in sales revenue in 2024 and 857 employees distributed between France and the United States (with 2 production sites in each country), LISI MEDICAL positions itself as a global partner offering a complete "more than a part" solution, from raw materials to finished products that are sterilized and packaged, ready for the operating room.

The division actively supports major medical equipment manufacturers (OEMs) in their growth through its recognized industrial expertise, innovation capacity and certified quality standards.

This acquisition project will allow LISI MEDCIAL to benefit from the full support of SK CAPITAL in the deployment of its strategy both in terms of organic growth and acquisitions.

Aaron Davenport, Managing Director at SK CAPITAL, declared, "Given LISI MEDICAL's highly engineered solutions and deep relationships with leading MedTech customers, the Company fits very well within the SK CAPITAL portfolio. SK CAPITAL has deep experience in the life sciences CDMO sector (Contract Development Manufacturing Organizations) and a long-standing track record of carving out businesses and establishing them as thriving, independent platforms, and we believe LISI MEDICAL represents an attractive opportunity to implement our transformational growth strategy."

Emmanuel Viellard, CEO of LISI Group, stated, "After 14 years of strong development and manufacturing consolidation within LISI Group, we are now looking forward to partner with SK CAPITAL and boost LISI MEDICAL's next development phase. Their strong track record in the life sciences sector and proven experience in France provide the essential strategic foresight and financial power to support the company going forward. This will also empower LISI MEDICAL to expand its offerings and capabilities, while solidifying its standing as a top-tier partner for leading MedTech OEMs. We are confident this transaction will be beneficial to all stakeholders of LISI MEDICAL, be it employees, clients or suppliers."

The transaction remains subject to consultation with the employee representative bodies of the relevant French entities as well as obtaining the required authorizations. Subject to receiving these necessary authorizations and opinions, the transaction could become effective during the second half of 2025.

LISI Group will comment on this transaction project, on next July 25th when announcing its first-half results for the period ended June 30, 2025.

LISI Contact SK CAPITAL Contact Emmanuel VIELLARD Jeremy MILNER (Gregroy FCA) Tel: +33 (0)3 84 57 00 77 Tel: +1 202 401-862-9422 Email: emmanuel.viellard@lisi-group.com Email: jmilner@gregoryfca.com Website: www.lisi-group.com Website: www.skcapitalpartners.com.

The LISI share is listed on Euronext, compartment A and belongs to the CAC® AERO & DEF., CAC® All Shares, CAC® Industrials indices, under ISIN code: FR 0000050353. Reuters Code: GFII.PA / Bloomberg Code: FII FP

LISI is a global industrial group with sales of nearly €1.8 billion in 2024 and a workforce of 10,262 people. It specializes in the manufacture of high value-added assembly solutions and components for the aerospace, automotive, and medical sectors. As a partner to the world's leading players and driven by long-standing family values, LISI innovates and invests in research and development for the products of tomorrow in order to meet its customers' needs, particularly in terms of quality, safety, and performance. The LISI Group stands out by relying on two strategic pillars: innovation and operational excellence, while integrating a strong CSR culture. For more information, visit www.lisi-group.com

SK CAPITAL is a transformational private investment firm with a disciplined focus on the specialty materials, ingredients, and life sciences sectors. The firm seeks to build resilient, sustainable, and growing businesses that create substantial long-term value. SK CAPITAL aims to utilize its industry, operating, and investment experience to identify opportunities to transform businesses into higher performing organizations with improved strategic positioning, growth, and profitability, as well as lower operating risk. SK CAPITAL currently has approximately \$10 billion in assets under management as of December 31, 2024. For more information, visit www.skcapitalpartners.com